Annovis Bio (ANVS) investor relations material

Executive summary

• Focused on late-stage clinical development of buntanetap for Alzheimer's and Parkinson's diseases, with pivotal Phase 3 trials ongoing and additional studies planned pending funding.

• Achieved 85% enrollment in Phase 3 Alzheimer's disease (AD) trial, with full enrollment expected by summer 2026 and top-line results in early 2027.

• NDA submission for buntanetap as a symptomatic AD treatment planned for early 2027, and as a disease-modifying treatment in early 2028.

• Published Phase 2/3 AD trial results in Nature NPJ Dementia, showing dose-dependent cognitive improvement and biomarker reductions.

• No product revenue to date; operations funded primarily through equity offerings and warrant issuances.

Financial highlights

• Net loss for Q1 2026 was $17.6 million, or $0.63 per share, compared to $5.5 million, or $0.32 per share, in Q1 2025, driven by increased R&D expenses.

• Operating expenses rose to $18.0 million from $6.3 million year-over-year, mainly due to higher clinical trial costs.

• Cash and cash equivalents were $14.2 million at March 31, 2026, down from $19.5 million at year-end 2025, excluding $10 million raised in April 2026.

• Net cash used in operating activities was $9.0 million for Q1 2026, up from $8.1 million in Q1 2025.

• 28.5 million shares of common stock outstanding as of March 31, 2026.

Outlook and guidance

• Current cash is expected to fund operations until Q4 2026; substantial additional capital will be needed for ongoing trials and commercialization.

• Full enrollment for Phase 3 AD trial expected in summer 2026; symptomatic data readout 6 months after last patient dosed, disease-modifying data at 18 months.

• NDA submission for buntanetap as symptomatic AD treatment planned for early 2027, and as disease-modifying treatment in early 2028.

• Management has concluded substantial doubt exists about the ability to continue as a going concern without new funding.

• Plans to raise additional capital through equity, debt, or other alternatives; may defer expenses if needed.